ORGO vs MDXG vs NVCR vs TELA vs APOG

For growth investors, MiMedx Group, Inc.

(MDXG) is the stronger pick with 20. 0% revenue growth year-over-year, versus 3. 2% for Apogee Enterprises, Inc. (APOG). MiMedx Group, Inc. (MDXG) offers the better valuation at 11. 4x trailing P/E (292. 8x forward), making it the more compelling value choice. Analysts rate Organogenesis Holdings Inc. (ORGO) a "Buy" — based on 5 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, MiMedx Group, Inc.

(MDXG) is the cheapest at 11. 4x versus Organogenesis Holdings Inc. at 17. 1x. On forward P/E, Apogee Enterprises, Inc. is actually cheaper at 10. 6x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Apogee Enterprises, Inc.

(APOG) delivered a total return of +13. 3%, compared to -92. 6% for TELA Bio, Inc. (TELA). Over 10 years, the gap is even starker: NVCR returned +31. 0% versus TELA's -92. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), TELA Bio, Inc.

(TELA) is the lower-risk stock at 0. 57β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately 287% more volatile than TELA relative to the S&P 500. On balance sheet safety, MiMedx Group, Inc. (MDXG) carries a lower debt/equity ratio of 9% versus 151% for TELA Bio, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), MiMedx Group, Inc.

(MDXG) is pulling ahead at 20. 0% versus 3. 2% for Apogee Enterprises, Inc. (APOG). On earnings-per-share growth, the picture is similar: Organogenesis Holdings Inc. grew EPS 1600% year-over-year, compared to -35. 2% for Apogee Enterprises, Inc.. Over a 3-year CAGR, TELA leads at 33. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

MiMedx Group, Inc.

(MDXG) is the more profitable company, earning 11. 6% net margin versus -54. 6% for TELA Bio, Inc. — meaning it keeps 11. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MDXG leads at 15. 3% versus -49. 2% for TELA. At the gross margin level — before operating expenses — MDXG leads at 82. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Apogee Enterprises, Inc.

(APOG) trades at 10. 6x forward P/E versus 292. 8x for MiMedx Group, Inc. — 282. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ORGO: 251. 6% to $9. 00.

In this comparison, ORGO (3.

4% yield), APOG (2. 8% yield) pay a dividend. MDXG, NVCR, TELA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, TELA Bio, Inc.

(TELA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 57)). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (TELA: -92. 6%, NVCR: +31. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (ORGO (Healthcare) and MDXG (Healthcare) and NVCR (Healthcare) and TELA (Healthcare) and APOG (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: ORGO is a small-cap high-growth stock; MDXG is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; TELA is a small-cap high-growth stock; APOG is a small-cap deep-value stock. ORGO, APOG pay a dividend while MDXG, NVCR, TELA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.